Reviews/Intermittent Fasting and Time Restricted Eating/Time-restricted eating reduces weight vs unrestricted eating
WL · IFTRE-WL-01 · v2
Across eleven randomized trials that compared time-restricted eating against eating without a time limit, people on the time-restricted schedule tended to lose a modest amount of weight, roughly a few percent of body weight. Several of these trials found the difference between groups was statistically reliable, including a 12-week trial [11], a 12-month trial [8], and a trial in people with type 2 diabetes [6]. However, one larger and widely cited trial [12] found essentially no difference between the time-restricted group and a group eating across the day. Most trials were small, short, and relied on participants reporting their own eating, and part of the benefit may simply come from eating less overall rather than from the timing itself. Taken together the direction of effect is consistent, but the modest size, the credible null result, and the quality limits are why the panel judged it probable rather than firmly established.
Eleven RCTs with an unrestricted or standard-care comparator consistently point to modest weight loss with time-restricted eating, on the order of 2-5% or 1-5 kg, measured as body weight directly rather than a surrogate. Statistically significant between-group effects appear in [11] (between-group difference -2.91 kg, p<0.001), [4] (-2.3 kg, P=.002), [6] (-3.56% vs control, P=.004) and [8] (-4.61 kg at 12 months, P<=0.01), with further reductions versus control reported in [2], [7], [9] (-1.8 kg and -1.3 kg, p=0.03), [10] (-2.61 kg, p<0.001) and [13] (-2%, p=0.04). The 12-month estimate in [8] indicates the effect can persist beyond the short trials. The outcome is consistent in direction across diverse populations. The contested point: The evidence divides on whether the between-group effect is real and robust: [12], a 116-participant trial against a consistent-meal-timing comparator, found no significant difference (-0.26 kg; 95% CI -1.30 to 0.78; P = .63), against a majority of trials showing modest loss. A second fault line is mechanism, since where energy intake was matched ([4], both arms energy-restricted) the window still helped but the effect was modest, leaving open whether timing acts independently or mainly through reduced intake.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Intermittent Fasting and Time Restricted Eating, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
TREAT [12], a 116-participant RCT with a direct unrestricted comparator, found no significant between-group weight difference (-0.26 kg; 95% CI -1.30 to 0.78; P = .63), directly contradicting the claim and capping confidence below the top tiers.
Most included trials are small and short (N=16 [13], N=20 [2], N=24 [10]; 4-14 weeks), limiting precision and durability; only [8] provides a 12-month controlled estimate.
Where it remains uncertain. The 116-participant TREAT trial [12] found no significant between-group difference (-0.26 kg; 95% CI -1.30 to 0.78; P = .63), and most other trials are small, short and unblinded.
Aleatory
Several trials are very small (N=16 [13], N=20 [2], N=24 [10]), so chance between-individual variation can swamp a modest timing effect.
Epistemic
Most trials run 4-14 weeks; only [8] provides a 12-month controlled estimate, so long-term maintenance of the effect is largely unobserved.
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct TRE vs unrestricted (non-TRE) contrast; significant weight reduction.
“Compared with non-TRE, TRE decreased the number of eating occasions, weight, lean mass, and visceral fat (all P ≤ 0.05).”
Panel auditInternal validity: low · scope of inference: Overweight/obese adults over 12 weeks; small feasibility signal that TRE lowers weight vs unrestricted eating.Key limitations: very small sample · feasibility design · lean mass also reduced
TRE significant vs control over 6 months in T2D.
“By month 6, body weight decreased significantly in the TRE group (-3.56% [95% CI, -5.92% to -1.20%]; P = .004) but not the CR group (-1.78% [95% CI, -3.67% to 0.11%]; P = .06), relative to controls.”
Panel auditInternal validity: high · scope of inference: Adults with obesity and type 2 diabetes over 6 months; TRE without calorie counting lowered weight vs control.Key limitations: single-centre · small sample · authors call for larger confirmatory RCTs
12-month RCT showing significant TRE weight loss vs an unrestricted (>=10h) control; supports durability.
“Compared with the control group, weight loss by month 12 was -4.61 kg (95% CI, -7.37 to -1.85 kg; P ≤ 0.01)”
Panel auditInternal validity: high · scope of inference: Racially diverse adults with obesity over 12 months; TRE lowered weight vs a less-restricted control.Key limitations: not blinded · not powered for between-group differences · no multiple-comparison adjustment
eTRF reduced body mass vs control in healthy non-obese adults; secondary outcome.
“eTRF, but not mTRF, improved fasting glucose, reduced total body mass and adiposity, ameliorated inflammation, and increased gut microbial diversity.”
Panel auditInternal validity: medium · scope of inference: Healthy adults without obesity over five weeks; effect on body mass present only for the early regimen.Key limitations: body mass not the primary outcome · no effect size or p-value for body mass · benefit confined to early TRF
4 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent direction and several significant controlled contrasts support the claim, but a credible null [12] plus mostly short, small, unblinded trials keep it at Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adequately powered long-term controlled trial. Most trials are small and short, and the credible null [12] versus the positive majority is unresolved; precision and durability are the binding limits. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large, multi-site RCT of TRE versus an unrestricted comparator with body weight at 12+ months as the primary endpoint and pre-specified power.
Open question: Does TRE produce durable weight loss beyond 12 months versus unrestricted eating? Why it is still open: Only [8] provides a 12-month controlled estimate; the remaining trials run 4-14 weeks, leaving longer-term maintenance unobserved.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19